Daratumumab is an IgG1k monoclonal antibody directed against CD38. CD38 is overexpressed in multiple myeloma cells. Daratumumab binds to a different CD38 epitope amino-acid sequence than does the anti-CD38 monoclonal antibody isatuximab. [20]
Antineoplastic agent; a recombinant humanized anti-CD38 monoclonal antibody. Uses for Daratumumab: Multiple Myeloma.
Daratumumab. Anti-CD38 monoclonal antibody, treatment of multiple myeloma. August 2024; Drugs of the Future 38(8): . 38(8):
drugs. We propose the use of chitosan nanoparticles (cNPS) as specific Anti-CD38 Targeted Nanoparticles for Drug Delivery in Multiple Myeloma. https
CD38 is a validated target for the treatment of multiple myeloma (MM). Daratumumab (Darzalex ), an anti-CD38 monoclonal antibody (mAb), has shown great clinical efficacy and has been approved for multiple myeloma treatment.
drug and an anti-CD38 monoclonal antibody -. - Anito-cel will be multiple myeloma program. Anito-cel is the first BCMA CAR T to be
Multiple Myeloma, drug therapy ; Isatuximab, A chimeric monoclonal antibody targeted against surface CD38 glycoproteins for the treatment of multiple myeloma in
Isatuximab is an anti-CD38 mAb intended to treat relapsed or refractory multiple myeloma. It entered in Phase II trials for multiple myeloma and T-cell
by LA Raedler Cited by 42Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma Multiple myeloma is a cancer of plasma cells
Comments